Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

(2019) Thomas Martin et al.   Blood Cancer Journal

Trends in Cause of Death among Patients with Multiple Myeloma in Puerto Rico and the United States SEER Population, 1987-2013

(2019) Maira A. Castañeda-Avila et al.   INTERNATIONAL JOURNAL OF CANCER

The Mechanism Of Action Of The Anti-CD38 Monoclonal Antibody Isatuximab In Multiple Myelmoa

(2019) Laura Moreno et al.   CLINICAL CANCER RESEARCH

A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

(2019) Joseph Mikhael et al.   BLOOD

In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab

(2019) Djordje Atanackovic et al.   LEUKEMIA

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

(2019) Thomas G. Martin et al.   Cells

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

(2019) Michel Attal et al.   LANCET

Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies

(2019) Mattia D'Agostino et al.   Cancers

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma

(2018) Cindy Varga et al.   BRITISH JOURNAL OF HAEMATOLOGY

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

(2018) Paul G Richardson et al.   Future Oncology

Phase I-b study of isatuximab + carfilzomib in relapsed and refractory multiple myeloma (RRMM).

(2018) Ajai Chari et al.   JOURNAL OF CLINICAL ONCOLOGY

CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance

(2018) Niels W.C.J. van de Donk et al.   Frontiers in Immunology

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

(2018) Paul G. Richardson et al.   Blood Cancer Journal

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma

(2018) Fabio Morandi et al.   Frontiers in Immunology

Multiple myeloma

(2017) Shaji K. Kumar et al.   Nature Reviews Disease Primers

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

(2016) Sagar Lonial et al.   LANCET

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

(2016) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD

(2016) Saad Usmani et al.   ONCOLOGIST

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

(2015) M. A. Dimopoulos et al.   HAEMATOLOGICA

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

(2015) J Laubach et al.   LEUKEMIA

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

(2015) M. A. Dimopoulos et al.   HAEMATOLOGICA

SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies

(2014) J. Deckert et al.   CLINICAL CANCER RESEARCH

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

(2014) S Vincent Rajkumar et al.   LANCET ONCOLOGY